Humedics Submits Marketing Authorization Application
News May 12, 2016
Humedics GmbH has announced that the company has submitted the marketing authorization application for the diagnostic agent necessary for the performance of the LiMAx test. The dossier was submitted in Germany, UK and Austria. After the successful closing of the clinical phase III study with the LiMAx test in September 2015, Humedics submitted the application for marketing authorization of the diagnostic agent in April 2016.
Submission was performed via the Decentralized Procedure in Germany, UK and Austria, with Germany being the reference member state. The “Fast-track LiveR” Trial with the investigational diagnostic agent 13C-Methacetin Solution for infusion was set up to demonstrate the positive impact of LiMAx test on patient management and diagnostic thinking related to postoperative management in patients undergoing partial liver resection.
Erwin de Buijzer, CEO of Humedics GmbH, stated: “After the successful closing of our phase III study we focused all of our efforts on preparing the marketing authorization dossier. This submission represents a breakthrough for the commercialization of our LiMAx test.” The recent submission for marketing authorization represents another milestone in the dynamic development of the company.
After closing a series C financing round end of 2014 and the successful certification of the FLIP medical device in 2015,Humedics’ team now focusses on the preparation of a successful European market entry of the diagnostic agent for the LiMAx test. The LiMAx test, in combination with the corresponding FLIP device and the diagnostic drug offers a clinically proven significant added value for patients with liver diseases and liver surgery. The LiMAx test is already being used in 17 top-tier university clinics in Europe.
Automated Robotic Device Enables Faster Blood TestingNews
Rutgers researchers have created an automated blood drawing and testing device that provides rapid results, potentially improving the workflow in hospitals and other health-related institutions to allow health care practitioners to spend more time treating patients.READ MORE
New Method to Quickly and Accurately Detect InfectionsNews
A new study by UTSA researchers describes a method that could show quickly and accurately whether a person has been infected with harmful bacteria or other pathogens.READ MORE
63 New Genetic Variations in DNA Increase Prostate Cancer RiskNews
A major new study of more than 140,000 men has identified 63 new genetic variations in the DNA code that increase the risk of prostate cancer.READ MORE
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018